Clinical trial · Observational
Fluorescence and Glioma Heterogeneity
Understanding the Mechanisms of ALA-induced Fluorescence in Malignant Gliomas - Exploring the Biological Basis of Tumoral Heterogeneity.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators aim to study the heterogeneity of fluorescence within malignant gliomas by sampling tissues from these variable areas within the same tumor. These tissue samples will then be subjected to pathological and biological analysis to assess proteins related to ALA metabolism and correlated with the fluorescence emitted as well as levels of protoporphyrin IX in the tissues.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Gliomas | Glioma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ALA | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- With ALA
- description
- Patients with malignant glioma. 25 patients will be provided the ALA for inducing fluorescence
- interventionNames
- Procedure: ALA
- label
- Without ALA
- description
- 5 tumor tissue samples from ACTREC tumor tissue repository will be obtained. These would be malignant gliomas or other brain tumor samples where ALA is usually not administered and will be used as controls and for calibration purposes
Primary outcomes (1)
- measure
- Degree of fluorescence
- timeFrame
- At the time of surgery within 72 hours
- description
- 1. Degree of fluorescence in different tumor regions 2. PPIX Qualification
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: Per-primum glioma * Adults (18-65 years) * Radiologically suspected malignant gliomas * Variable contrast enhancement on MRI (patchy and/or non-uniform) * Eligible for surgical therapy (craniotomy NOT stereotactic biopsy ) * No contraindication for surgery Exclusion Criteria: * Poor general condition (KPS \< 70) * Prior treatment (except biopsy) * Compromised renal/hepatic function * Immunocompromised status * Known photosensitivity / allergy to 5-ALA
References
Publications (0)
Data not yet available